NanoVibronix Adjourns Special Meeting of Stockholders
April 27 2021 - 11:17AM
NanoVibronix, Inc. (the “
Company”)
(NASDAQ:
NAOV) announced today that the Company’s Special Meeting of
Stockholders, which had been previously adjourned to 10:00 a.m.
Eastern time today, April 27, 2021, has been once again adjourned
to allow for more time for stockholders to vote. The meeting has
been scheduled to reconvene on May 6, 2021 at 10:00 a.m. Eastern
time and will be held virtually online at
www.virtualshareholdermeeting.com/NAOV2021SM.
During the period of the adjournment, the Company will continue
to solicit proxies from its stockholders with respect to the
proposals set forth in the Company’s proxy statement. Proxies
previously submitted in respect to the Special Meeting will be
voted at the reconvened meeting unless properly revoked.
The Company encourages all stockholders who have not yet
voted to do so before May 5, 2021 at 11.59 p.m. Eastern time. The
stockholders may vote by internet at www.proxyvote.com, or by
telephone at 1-800-690-6903 for stockholders of record and
1-800-454-8683 for beneficial stockholders, or by returning a
properly executed proxy card to Vote Processing, c/o Broadridge, 51
Mercedes Way, Edgewood, NY 11717.
If you have any questions, need additional material, or need
assistance in voting your shares, please feel free to contact the
firm assisting the Company in the solicitation of proxies,
Kingsdale Advisors. Brokers, banks and other nominees may call
416-867-2272. Stockholders may call toll-free 1-877-657-5856. Or
you may contact Kingsdale Advisors by email at
contactus@kingsdaleadvisors.com.
About NanoVibronix
NanoVibronix Inc. (NASDAQ: NAOV) is a medical
device company headquartered in Elmsford, New York, with research
and development in Nesher, Israel, which is focused on developing
medical devices utilizing its proprietary and patented low
intensity surface acoustic wave (SAW) technology. This technology
allows for the creation of low-frequency ultrasound waves that can
be utilized for a variety of medical applications, including the
disruption of biofilms and bacteria colonization, as well as
providing pain relief. The devices can be administered at home
without the assistance of medical professionals. The Company’s
primary products include PainShield®, UroShield™ and WoundShield™.
Additional information about the Company is available at:
www.nanovibronix.com.
Additional Information and where to find it
The Company has filed a definitive proxy statement
and associated proxy card with the U.S. Securities and Exchange
Commission (the “SEC”) in connection with the solicitation of
proxies for the Special Meeting of Stockholders of the Company (the
“Special Meeting”). The Company, its directors, its executive
officers and certain other individuals set forth in the definitive
proxy statement will be deemed participants in the solicitation of
proxies from shareholders in respect of the Special Meeting.
Information regarding the names of the Company’s directors and
executive officers and certain other individuals and their
respective interests in the Company by security holdings or
otherwise are set forth in the definitive proxy statement filed
with the SEC on March 3, 2021. BEFORE MAKING ANY VOTING DECISION,
STOCKHOLDERS OF THE COMPANY ARE URGED TO READ ALL RELEVANT
DOCUMENTS FILED WITH OR FURNISHED TO THE SEC, INCLUDING THE
DEFINITIVE PROXY STATEMENT AND ANY SUPPLEMENTS THERETO AND
ACCOMPANYING PROXY CARD, BECAUSE THEY CONTAIN IMPORTANT
INFORMATION. Investors and shareholders can obtain a copy of the
documents filed by the Company with the SEC, including the
definitive proxy statement, free of charge by visiting the SEC’s
website, www.sec.gov. The Company’s stockholders can also obtain,
without charge, a copy of the definitive proxy statement and other
relevant filed documents when available from the Company’s website
at https://ir.nanovibronix.com/sec-filings.
Forward-looking Statements
This press release contains “forward-looking
statements.” Such statements may be preceded by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words. Forward-looking statements are not
guarantees of future performance, are based on certain assumptions
and are subject to various known and unknown risks and
uncertainties, many of which are beyond the Company’s control, and
cannot be predicted or quantified and consequently, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include,
without limitation, risks and uncertainties associated with (i)
market acceptance of our existing and new products or lengthy
product delays in key markets; (ii) negative or unreliable clinical
trial results (iii) an inability to secure regulatory approvals for
the sale of our products, (iv) intense competition in the medical
device industry from much larger, multinational companies, (v)
product liability claims, (vi) product malfunctions, (vii) our
limited manufacturing capabilities and reliance on subcontractors
for assistance, (viii) insufficient or inadequate reimbursement by
governmental and other third party payers for our products, (ix)
our efforts to successfully obtain and maintain intellectual
property protection covering our products, which may not be
successful, (x) legislative or regulatory reform of the healthcare
system in both the U.S. and foreign jurisdictions, (xi) our
reliance on single suppliers for certain product components, (xii)
the fact that we will need to raise additional capital to meet our
business requirements in the future and that such capital may not
be available, or may be costly, dilutive or difficult to obtain and
(xiii) the fact that we conduct business in multiple foreign
jurisdictions, exposing us to foreign currency exchange rate
fluctuations, logistical and communications challenges, burdens and
costs of compliance with foreign laws and political and economic
instability in each jurisdiction. More detailed information about
the Company and the risk factors that may affect the realization of
forward looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s web site at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Brian Murphy
Nanovibronix Inc.
bmurphy@nanovibronix.com
Brett Maas
Hayden IR, LLC
(646) 536-7331
brett@haydenir.com
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From May 2024 to Jun 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Jun 2023 to Jun 2024